Neumora Therapeutics, Inc.
Public company- Headquarters
- WATERTOWN, Massachusetts
- Industry
- Biotechnology
- Ticker
- NMRA
- CIK
- 0001885522
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| CEOJoshua Pinto, Ph.D. | Aug 14, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- Eloxx Pharmaceuticals, Inc.
director appointed: Geno J. Germano
- Voyager Therapeutics, Inc.
president appointed: Robin Swartz
- TScan Therapeutics, Inc.
Director departs: Garry Nicholson
- Moderna, Inc.
COO appointed: Juan Andres
- Executive appointment
CEO appointed: Joshua Pinto, Ph.D.
Joshua Pinto, Ph.D. was named Chief Executive Officer of Neumora Therapeutics, Inc., effective August 14, 2026. Joshua Pinto, Ph.D. succeeds Paul L. Berns. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 14, 2026Role: Chief Executive Officer
Only one public record so far. We add events as soon as a new filing lands; watch Neumora Therapeutics, Inc. to get them in your digest.
Last verified Nov 8, 2026